Vaccination against atherosclerosis: An overview
Atherosclerosis, an inflammatory disorder involving innate and adaptive immune responses with both atheroprotective and proatherogenic roles, is a life wasting and economic demanding disorder that continues to be the leading cause of morbidity and mortality worldwide. Thus, the need for a long-lasti...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-03-01
|
| Series: | Hellenic Journal of Cardiology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1109966619301253 |
| _version_ | 1819082829023150080 |
|---|---|
| author | Hamideh Amirfakhryan |
| author_facet | Hamideh Amirfakhryan |
| author_sort | Hamideh Amirfakhryan |
| collection | DOAJ |
| description | Atherosclerosis, an inflammatory disorder involving innate and adaptive immune responses with both atheroprotective and proatherogenic roles, is a life wasting and economic demanding disorder that continues to be the leading cause of morbidity and mortality worldwide. Thus, the need for a long-lasting and highly effective treatment has made researchers to find new strategies. Many efforts made thus far to reduce the burden of the disease have been toward the modification of cardiovascular risk factors.Vaccination against atherosclerosis has been investigated as a promising strategy to overcome the disorder. Several kinds of vaccination methods have been investigated mostly in mice, with promising results in the attenuation of atherosclerosis, inflammation, and lipid concentration. The most conflicting part of this strategy is finding appropriate antigens and adjuvants. Some antigens have been used, including OxLDL, apoB100, CETP, PCSK9, HSP60, MHC-II-derived peptides, and interleukins. The DNA-based vaccination method has opened a new window in this field. There is an increasing necessity for developing an effective, economical, long-lasting, accessible, and convenient vaccination method. There are large gaps in evidence for the selection of proper human sampling to test the vaccines, route of delivery, safety, strength, scheduling, and side effects, all of which must be considered in clinical trials in the future. |
| first_indexed | 2024-12-21T20:22:53Z |
| format | Article |
| id | doaj.art-5ab6fa9504734f59bbc853e78c81bf3c |
| institution | Directory Open Access Journal |
| issn | 1109-9666 |
| language | English |
| last_indexed | 2024-12-21T20:22:53Z |
| publishDate | 2020-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hellenic Journal of Cardiology |
| spelling | doaj.art-5ab6fa9504734f59bbc853e78c81bf3c2022-12-21T18:51:26ZengElsevierHellenic Journal of Cardiology1109-96662020-03-016127891Vaccination against atherosclerosis: An overviewHamideh Amirfakhryan0Preventative Cardiovascular Medicine, University of South Wales, Faculty of Health Science, Edificio Soller, 32/4, Calle Nenufar, Los Pacos, 29640 Fuengirola, Malaga, SpainAtherosclerosis, an inflammatory disorder involving innate and adaptive immune responses with both atheroprotective and proatherogenic roles, is a life wasting and economic demanding disorder that continues to be the leading cause of morbidity and mortality worldwide. Thus, the need for a long-lasting and highly effective treatment has made researchers to find new strategies. Many efforts made thus far to reduce the burden of the disease have been toward the modification of cardiovascular risk factors.Vaccination against atherosclerosis has been investigated as a promising strategy to overcome the disorder. Several kinds of vaccination methods have been investigated mostly in mice, with promising results in the attenuation of atherosclerosis, inflammation, and lipid concentration. The most conflicting part of this strategy is finding appropriate antigens and adjuvants. Some antigens have been used, including OxLDL, apoB100, CETP, PCSK9, HSP60, MHC-II-derived peptides, and interleukins. The DNA-based vaccination method has opened a new window in this field. There is an increasing necessity for developing an effective, economical, long-lasting, accessible, and convenient vaccination method. There are large gaps in evidence for the selection of proper human sampling to test the vaccines, route of delivery, safety, strength, scheduling, and side effects, all of which must be considered in clinical trials in the future.http://www.sciencedirect.com/science/article/pii/S1109966619301253VaccinationAtherosclerosisInflammationImmunizationAntigen |
| spellingShingle | Hamideh Amirfakhryan Vaccination against atherosclerosis: An overview Hellenic Journal of Cardiology Vaccination Atherosclerosis Inflammation Immunization Antigen |
| title | Vaccination against atherosclerosis: An overview |
| title_full | Vaccination against atherosclerosis: An overview |
| title_fullStr | Vaccination against atherosclerosis: An overview |
| title_full_unstemmed | Vaccination against atherosclerosis: An overview |
| title_short | Vaccination against atherosclerosis: An overview |
| title_sort | vaccination against atherosclerosis an overview |
| topic | Vaccination Atherosclerosis Inflammation Immunization Antigen |
| url | http://www.sciencedirect.com/science/article/pii/S1109966619301253 |
| work_keys_str_mv | AT hamidehamirfakhryan vaccinationagainstatherosclerosisanoverview |